Gamifant® (emapalumab-lzsg)

Gamifant (emapalumab‑lzsg) is covered for adult and pediatric primary HLH and for HLH/MAS associated with Still’s disease/sJIA only when required diagnostic criteria are met (primary HLH: molecular diagnosis or ≥5 HLH criteria; HLH/MAS: ferritin >684 ng/mL plus ≥2 specified abnormalities) and after failure or intolerance of conventional HLH therapy (or inadequate response/intolerance to high‑dose IV corticosteroids for HLH/MAS). Approvals are time‑limited (6 months for primary HLH; 8 weeks for HLH/MAS), require specialist prescribing/consultation, baseline lab and prior‑therapy documentation, and adherence to specified dosing with titration permitted up to 10 mg/kg.

"Primary hemophagocytic lymphohistiocytosis (HLH) in adult and pediatric patients with refractory, recurrent, or progressive disease, or intolerance with conventional HLH therapy."

Sign up to see full coverage criteria, indications, and limitations.